These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28122713)

  • 1. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.
    Nistala R; Savin V
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F661-F670. PubMed ID: 28122713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
    Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
    Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
    Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension.
    Cappetta D; Ciuffreda LP; Cozzolino A; Esposito G; Scavone C; Sapio L; Naviglio S; D'Amario D; Crea F; Rossi F; Berrino L; De Angelis A; Urbanek K
    Oxid Med Cell Longev; 2019; 2019():8912768. PubMed ID: 30774748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.
    Nistala R; Meuth AI; Smith C; An J; Habibi J; Hayden MR; Johnson M; Aroor A; Whaley-Connell A; Sowers JR; McKarns SC; Bender SB
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F505-F517. PubMed ID: 33522410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD.
    Benetti A; Martins FL; Sene LB; Shimizu MHM; Seguro AC; Luchi WM; Girardi ACC
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F285-F296. PubMed ID: 33346727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
    Klemann C; Wagner L; Stephan M; von Hörsten S
    Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
    Lim SW; Jin JZ; Jin L; Jin J; Li C
    Korean J Intern Med; 2015 Nov; 30(6):759-70. PubMed ID: 26552451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis.
    Kawase H; Bando YK; Nishimura K; Aoyama M; Monji A; Murohara T
    J Mol Cell Cardiol; 2016 Sep; 98():37-47. PubMed ID: 27374118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway.
    Zhang Q; He L; Dong Y; Fei Y; Wen J; Li X; Guan J; Liu F; Zhou T; Li Z; Fan Y; Wang N
    FASEB J; 2020 Jun; 34(6):7500-7519. PubMed ID: 32281218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
    Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
    Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
    Ohm B; Moneke I; Jungraithmayr W
    Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
    Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.
    Wolke C; Teumer A; Endlich K; Endlich N; Rettig R; Stracke S; Fiene B; Aymanns S; Felix SB; Hannemann A; Lendeckel U
    Exp Biol Med (Maywood); 2017 Mar; 242(5):554-563. PubMed ID: 28038565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.
    Nistala R; Habibi J; Lastra G; Manrique C; Aroor AR; Hayden MR; Garro M; Meuth A; Johnson M; Whaley-Connell A; Sowers JR
    Endocrinology; 2014 Jun; 155(6):2266-76. PubMed ID: 24712875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.